Pimecrolimus is a topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons. Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel.
- Mechanism
- Curator reviewed
Pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE.
- Primary indication
- For treatment of mild to moderate atopic dermatitis.Curator reviewed · 4 structured indications
- Formula / weight
- C43H68ClNO11 · 810.46 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2001
- Code names
- ASM 981 · SDZ ASM-981
- Brand names
Resolves to
KASDHRXLYQOAKZ-XDSKOBMDSA-NSMILES[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OCWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Pimecrolimus, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account